Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg
NCT02206295
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
80
Enrollment
INDUSTRY
Sponsor class
Conditions
Bioequivalence
Interventions
DRUG:
selexipag
Sponsor
Actelion